SCHEMBL4199926

SCHEMBL4199926

NC(CN(c1ccccc1)c1ccccc1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPI P09923 1/20 0.52
PKM P14618 1/20 0.52
PTGS1 P23219 1/20 0.52
XIAP P98170 1/20 0.52
SLC7A5 Q01650 1/20 0.52
KIF11 P52732 4/20 0.44
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44
GRM2 Q14416 1/20 0.44
GRM3 Q14832 1/20 0.44
KDM4E B2RXH2 2/20 0.42
KYNU Q16719 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 1/20 0.41
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4199918 1.00 ALPI (0.52) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL2836743 0.86 ALPI (0.41) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL3930879 0.81 CYP2D6 (0.46) KIF11SLC1A3SLC1A2SLC1A1
SCHEMBL25358402 0.81 ALPI (0.48) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL31369636 0.81 ALPI (0.48) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL25358407 0.81 ALPI (0.48) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL2703603 0.80 LTA4H (0.51) KIF11KDM4EL3MBTL1POLBAPOBEC3A
SCHEMBL2703155 0.80 LTA4H (0.51) KIF11KDM4EL3MBTL1POLBAPOBEC3A
SCHEMBL542094 0.78 PTGS1 (0.42) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL8113492 0.78 KDM4E (0.47) KDM4EL3MBTL1POLBAPOBEC3AAPOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809358-B2 Use of IκB-kinase inhibitors in pain therapy SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2014-08-19 US disclosed
US-20090069358-A1 Use of IKappaB-Kinase Inhibitors in Pain Therapy SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-03-12 US disclosed
US-7462638-B2 Use of IκB-kinase inhibitors in pain therapy SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-12-09 US disclosed
US-7285560-B2 Indole derivatives or benzimidazole derivatives for modulating IκB kinase SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-10-23 US disclosed
US-20070244139-A1 Indole Derivatives or Benzimidazole Derivatives for Modulating IkB Kinase SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-10-18 US disclosed
US-20050197353-A1 Indole derivatives or benzimidazole derivatives for modulating IkB kinase AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-09-08 US disclosed
US-20040116494-A1 Use of IkappaB-kinase inhibitors in pain therapy AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-06-17 US disclosed
US-6166072-A Amino acid derivatives ALLELIX NEUROSCIENCE, INC. (CA) 2000-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244139-A1 Indole Derivatives or Benzimidazole Derivatives for Modulating IkB Kinase IKBKB, IKBKG, IKBKE ALPI 962/4885PKM 503/4885PTGS1 573/4885
US-20090069358-A1 Use of IKappaB-Kinase Inhibitors in Pain Therapy NFKBIA, IKBKB, IKBKE ALPI 991/4885PKM 1173/4885PTGS1 26/4885
US-20050197353-A1 Indole derivatives or benzimidazole derivatives for modulating IkB kinase IKBKB, IKBKG, IKBKE ALPI 962/4885PKM 503/4885PTGS1 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.